The first clinical evidence of the potential beneficial effects of the treatment with a DHFR inhibitor in the COVID-19 disease was observed in patients receiving MTX for treating psoriasis or rheumatoid arthritis [59,60,61,62,63,64,65]. This evidence concerns the gene DHFR and psoriasis.